Bioray Laboratories of Shanghai reported positive initial results from a test of its gene-edited CAR-T therapy. The company uses gene editing to form a PD1-knockin CAR-T molecule, which it has administered to patients with relapsed/refractory B-cell non-Hodgkin lymphoma. The non-viral PD1 specific targeted CAR-T therapy is constructed by inserting a CAR cassette into a PD1 locus without using a virus, generating the CAR-T product in one step. More details.... Share this with colleagues: // //